Prediction of late restenosis after sirolimus-eluting stent implantation using serial quantitative angiographic and intravascular ultrasound analysis

被引：1

作者：

Funada R. ^{[1
]}

Oikawa Y. ^{[1
]}

Yajima J. ^{[1
]}

Matsuno S. ^{[1
]}

Kano H. ^{[1
]}

Kirigaya H. ^{[1
]}

Nagashima K. ^{[1
]}

Kurabayashi M. ^{[2
]}

Aizawa T. ^{[1
]}

机构：

[1] Department of Cardiology, The Cardiovascular Institute Hospital, Tokyo 106-0032

[2] Department of Medicine and Biological Science, Gunma University Graduate School of Medicine, Gunma

来源：

Cardiovascular Intervention and Therapeutics | 2011年 / 26卷 / 1期

关键词：

Intravascular ultrasound; Late restenosis; Late stent thrombosis; Sirolimus-eluting stent;

D O I：

10.1007/s12928-010-0030-3

中图分类号：

学科分类号：

摘要：

Although sirolimus-eluting stents (SESs) have shown to significantly reduce the incidence of restenosis, it remains unclear when the follow-up angiography should be performed after SES implantation. A total of 868 patients with 1,574 lesions were treated with SES. Of the 71 patients with 87 lesions were performed serial angiographic and intravascular ultrasound (IVUS) analysis (pre, post, 1st and 2nd-follow-up). The first follow-up period was 7.9 ± 3.5 months and the second follow-up was 18.9 ± 7.7 months. Late restenosis (LR) was defined as diameter stenosis ≥50% at second follow-up, which was <50% at first follow-up. A total of restenosis was documented in 69 patients with 89 lesions (5.7%) overall, 13 lesions (3.2%) led to LR. Angiographic pattern of LR was predominately focal pattern. In LR group, late lumen loss by angiography was increased between 1st-follow-up and 2nd-follow-up (0.69 ± 0.41 mm in first follow-up and 1.98 ± 0.44 mm in second follow-up, p < 0.0001). Minimum lumen area (MLA) by IVUS had slightly decreased already in 1st-follow-up (6.07 ± 2.31 mm 2 in post procedure and 4.71 ± 2.05 mm 2 in 1st-follow-up, p = 0.098) and significantly decreased in 2nd-follow-up (6.07 ± 2. 31 mm 2 in post procedure and 1.71 ± 0.93 mm 2 in 2nd-follow-up, p < 0.0001). However, in each period, there were no significant difference in both late lumen loss and MLA in non-LR group. Neointima growth prolonged gradually over 1 year in LR group. These findings suggest that if neointimal proliferation is recognized in short-term-follow-up period, long-follow-up should be needed. © 2010 Japanese Association of Cardiovascular Intervention and Therapeutics.

引用

页码：26 / 32

页数：6

共 23 条

[1]

Morice M.-C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Et al., A randomized comparison of a sirolimus-eluting stent with a standard s tent for coronary revascularization, N Engl J Med, 346, pp. 1773-1780, (2002)

[2]

Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Et al., Sirolimus-eluting stents versus standard stent in patients with stenosis in a native coronary artery, N Engl J Med, 349, pp. 1315-1323, (2003)

[3]

Schofer J., Schluter M., Gershilick A.H., Wijns W., Garcia E., Schampaert E., Breithardt G., Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS), Lancet, 362, pp. 1093-1099, (2003)

[4]

Schampaert E., Cohen E.A., Schluter M., Reeves F., Traboulsi M., Title L.M., Kuntz R.E., Et al., The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS), J Am Coll Cardiol, 43, pp. 1110-1115, (2004)

[5]

Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., Turco M., Et al., One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial, Circulation, 109, pp. 1942-1947, (2004)

[6]

Virmani R., Liistro F., Stankovic G., Di Mario C., Montorfano M., Farb A., Kolodgie F.D., Et al., Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans, Circulation, 106, pp. 2649-2651, (2002)

[7]

Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E., Kutys R., Et al., Pathology of drug-eluting stents in humans: delayed healin g and late thrombotic risk, J Am Coll Cardiol, 48, pp. 193-202, (2006)

[8]

Finn A.V., Nakazawa G., Joner M., Kolodgie F.D., Mont E.K., Gold H.K., Virmani R., Vascular responses to drug eluting stents: importance of delayed dealing, Arteroscler Thromb Vasc Biol, 27, pp. 1500-1510, (2007)

[9]

Aoki J., Abizaid A.C., Serruys P.W., Ong A.T., Boersma E., Sousa J.E., Bruining N., Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients, J Am Coll Cardiol, 46, pp. 1670-1676, (2005)

[10]

Cosgrave J., Corbett S.J., Melzi G., Babic R., Biondi-Zoccai G.G., Airoldi F., Chieffo A., Et al., Late restenosis following sirolimus-eluting stent implantation, Am J Cardiol, 100, pp. 41-44, (2007)

← 1 2 3 →